Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer communications"
DOI: 10.1002/cac2.12214
Abstract: BACKGROUND Current treatment options for human epidermal growth factor receptor 2 (HER2)-overexpressing gastric cancer at third-line have shown limited clinical benefit. Further, there is no specific treatment for HER2 immunohistochemistry (IHC) 2+ and fluorescence in-situ… read more here.
Keywords: patients her2; her2 overexpressing; junction cancer; gastroesophageal junction ... See more keywords
Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer medicine"
DOI: 10.1002/cam4.5893
Abstract: The antibody-drug conjugate trastuzumab emtansine (T-DM1) is approved for human epidermal growth factor receptor 2 (HER2/ERBB2)-positive breast cancer. We aimed to study tumor HER2 expression and its effects on T-DM1 responses in patients with HER2-positive… read more here.
Keywords: cancer; patients her2; urothelial bladder; her2 positive ... See more keywords
The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction.
Sign Up to like & getrecommendations! Published in 2022 at "International journal of cancer"
DOI: 10.1002/ijc.34024
Abstract: We investigated the effect of trastuzumab on cardiac function in a real-world historic cohort of patients with HER2-positive metastatic breast cancer (MBC) with reduced baseline left ventricular ejection fraction (LVEF). Thirty-seven patients with HER2-positive MBC… read more here.
Keywords: severe cardiotoxicity; patients her2; cancer; her2 positive ... See more keywords
Reply to Kadri Altundag
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.24838
Abstract: We thankKadri for his discussion of our recent article entitled “Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer.” The questions posed by Kadri et al question… read more here.
Keywords: patients her2; adjuvant trastuzumab; her2 loss; neoadjuvant chemotherapy ... See more keywords
Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-018-3753-y
Abstract: PurposeTo investigate the safety and efficacy of 30-min maintenance infusions of trastuzumab in advanced gastric cancer positive for human epidermal growth factor receptor 2 (HER2).MethodsThis was a retrospective study conducted across five Korean hospitals in… read more here.
Keywords: advanced gastric; patients her2; infusion; gastric cancer ... See more keywords
Pharmacokinetic and exposure–response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-019-03871-w
Abstract: PurposeTo characterize the pharmacokinetics (PK) of pertuzumab and trastuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer in the randomized, double-blind, phase III JACOB study (NCT01774786), and to evaluate the appropriateness of the… read more here.
Keywords: pertuzumab trastuzumab; patients her2; her2 positive; pertuzumab ... See more keywords
Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-019-03991-3
Abstract: Trastuzumab (T-mab) combined with cisplatin and fluoropyrimidines is a standard first-line treatment for HER2+ advanced gastric cancer (AGC). We conducted the first phase II trial among four Japanese study groups to assess the efficacy and… read more here.
Keywords: patients her2; gastric cancer; study; cancer ... See more keywords
Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06)
Sign Up to like & getrecommendations! Published in 2017 at "Gastric Cancer"
DOI: 10.1007/s10120-017-0766-x
Abstract: BackgroundS-1 plus cisplatin is a standard regimen for advanced gastric cancer (AGC) in Asia. The ToGA trial established a fluoropyrimidine plus cisplatin and trastuzumab as a standard treatment for human epidermal growth factor receptor 2… read more here.
Keywords: patients her2; her2 positive; gastric cancer; elderly patients ... See more keywords
Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer
Sign Up to like & getrecommendations! Published in 2019 at "Gastric Cancer"
DOI: 10.1007/s10120-019-00973-5
Abstract: BackgroundTrastuzumab with cisplatin and fluoropyrimidines improves overall survival (OS) in patients with HER2-positive advanced gastric cancer (AGC). S-1 plus oxaliplatin (SOX) is one of the standard regimens for HER2-negative AGC in Japan. However, few studies… read more here.
Keywords: patients her2; her2 positive; gastric cancer; agc ... See more keywords
Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer
Sign Up to like & getrecommendations! Published in 2019 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-019-05198-9
Abstract: PurposeSeveral clinical trials have investigated the prognostic and predictive usefulness of molecular markers. With limited predictive value, molecular markers have mainly been used to identify prognostic subgroups in which the indication for chemotherapy is doubtful… read more here.
Keywords: patients her2; breast; early breast; subgroups patients ... See more keywords
Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC)
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-16-1496
Abstract: Purpose: ONT-380 (ARRY-380) is a potent and selective oral HER2 inhibitor. This Phase I study determined the MTD, pharmacokinetics (PK) and antitumor activity of ONT-380 in HER2-positive advanced solid tumors, with an expansion cohort of… read more here.
Keywords: patients her2; solid tumors; expansion cohort; ont 380 ... See more keywords